leadcare recruitment Notices and Updates Us | Leadcare Recruitment
info@leadcarerecruitment.com
028 7187 6515
Facebook Instagram Linkedin
Fast Track Apply
Menu
info@leadcarerecruitment.com
028 7187 6515
Leadcare Recruitment Agency Logo

Notices and Updates

HSS(MD) 10 2024 – UPDATE TO COVID-19 TESTING GUIDANCE HSS(MD) CIRCULARS WITHDRAWN

HSS(MD) 09 2024 – NATIONAL PATIENT SAFETY ALERT – SHORTAGE OF SALBUTAMOL 2.5MG 2.5ML AND 5MG 2.5ML NEBULISER LIQUID UNIT DOSE VIALS

HSS(MD) 08 2024 – MHRA DRUG SAFETY UPDATE – PSEUDOEPHEDRINE VERY RARE RISK OF POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES) AND REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME (RCVS)

HSS(MD) 07 2024 – MHRA DRUG SAFETY UPDATE – CODEINE LINCTUS (CODEINE ORAL SOLUTIONS) RECLASSIFICATION TO PRESCRIPTION-ONLY MEDICINE

HSS MD 5 2024 lMEASLES, MUMPS AND RUBELLA CATCH-UP CAMPAIGN FEBRUARY TO MARCH 2024

HSS(MD) 47 2023 – THE 2023 24 SEASONAL INFLUENZA AND COVID-19 VACCINATION PROGRAMMES FOR HEALTH AND SOCIAL CARE WORKERS

HSS MD 46 2023 COVID-19 AUTUMNWINTER BOOSTER VACCINATION PROGRAMME 2023

HSS(MD) 43 2023 – SEASONAL INFLUENZA VACCINATION PROGRAMME 2023 24

HSS(MD) 40/2023 WORLD PATIENT SAFETY DAY 17 SEPTEMBER 2023

HSS(MD) 35/2023 – MHRA DRUG SAFETY UPDATE AND NATIONAL PATIENT SAFETY ALERT- CALCIUM CHLORIDE, CALCIUM GLUCONATE: POTENTIAL RISK OF UNDERDOSING WITH CALCIUM GLUCONATE IN SEVERE HYPERKALAEMIA

HSS(MD) 34 2023 – MHRA DRUG SAFETY UPDATE – NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) – POTENTIAL RISKS FOLLOWING PROLONGED USE AFTER 20 WEEKS OF PREGNANCY

National Institute for Health and Care Excellence (NICE) Covid-19 Rapid Guidance – ~ June 2023

HSS(MD) 33 2023 – MHRA DRUG SAFETY UPDATE – ADRENALINE AUTO-INJECTORS (AAIS) NEW GUIDANCE AND RESOURCES FOR SAFE USE

HSS(MD) 32 2023 – COVID-19 TREATMENTS – AMENDED INDEPENDENT ADVISORY GROUP REPORT OF HIGHEST RISK GROUPS

Management of Constipation in Adults with Dysphagia

Use of gum-based thickeners with Polyethylene glycol laxatives (Macrogols)

HSS MD 18 2023 UPDATED COVID-19 TESTING GUIDANCE TO SUPPORT CLINICAL PATHWAYS

HSS MD 17 2023 – UK STRATEGY FOR MPOX (FORMERLY KNOWN AS MONKEYPOX) CONTROL

HSS MD 16 2023 – CHANGES TO THE HPV VACCINATION SCHEDULE – REDUCTION TO ONE DOSE

HSS MD 15 2023 – JCVI Advice for 2023 ~ 19 Spring Booster Programme and changes to the primary course offer

UK Strategy for Mpox Control

MEALTIMES MATTER FRAMEWORK FINAL VERSION 29TH NOVEMBER 2022

BW2130 Winter regulator letter medical

HSS(MD) 51 2022 – LETTER TO ALL FRONTLINE HEALTH AND SOCIAL CARE WORKERS – ENCOURAGING EVERYONE TO BE VACCINATED FOR INFLUENZA AND COVID-19 THIS AUTUMN / WINTER

HSS(MD) 50 2022 – UPDATED COVID-19 TESTING GUIDANCE TO SUPPORT CLINICAL PATHWAYS

HSS MD 49 2022 – PUBLIC HEALTH MESSAGE TO ALL HEALTH AND SOCIAL CARE PROVIDERS REGARDING EBOLA VIRUS OUTBREAK IN UGANDA (SUDAN EBOLAVIRUS)

Letter from Prof Sir Michael McBride – PAUSE OF ASYMPTOMATIC TESTING FOR HEALTH AND SOCIAL CARE WORKERS AND FOR HOSPITAL VISITORS

HSS(MD) 37 2022 – WORLD PATIENT SAFETY DAY 17 SEPTEMBER 2022

National Institute for Health and Care Excellence (NICE) Covid-19 Rapid Guidance – ~ June 2022

HSS(MD) 45 2022 – TECOVIRIMAT AS A TREATMENT FOR PATIENTS HOSPITALISED DUE TO MONKEYPOX VIRAL INFECTION

HSS(MD) 43 2022 – EUROPEAN MEDICINES AGENCY (EMA) APPROVAL OF COMIRNATY AND SPIKEVAX BIVALENT ORIGINAL / OMICRON BA.1 COVID-19 VACCINES

HSS(MD) 42 2022 – SHINGLES VACCINATION PROGRAMME – ELIGIBILITY CRITERIA

ADDENDUM to HSS(MD) 37/2022- WORLD PATIENT SAFETY DAY 17 SEPTEMBER 2022 EVENTS POSTPONED

NatPSA_P.aeruginosa_contamination_24062022

HSC (SQSD) 16 22 Inadvertent oral administration of potassium permanganate

HSS MD 21 2022 – PERMANENT SUSPENSION OF THE 15 MINUTE WITH COVID-19 VACCINES

HSS MD 20 2022 – COVID-19 TREATMENTS FOR NON-HOSPITALISED PATIENTS

HSS MD 13 2022 COVID-19 SPRING BOOSTER VACCINATION PROGRAMME

HSS MD 9 2022 JCVI UPDATE ON ADVICE FOR PRIMARY COVID-19 VACCINATION OF CHILDREN AGED 5 TO 11 YEARS

HSS MD 2 2022 – MANAGEMENT OF HEALTH AND SOCIAL CARE STAFF WHO ARE CONFIRMED CASES OF COVID-19 – UPDATED GUIDANCE